<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01460602</url>
  </required_header>
  <id_info>
    <org_study_id>X05266</org_study_id>
    <nct_id>NCT01460602</nct_id>
  </id_info>
  <brief_title>Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma</brief_title>
  <official_title>Phase 1/2 Study of VELCADE (Bortezomib), Nipent (Pentostatin), and Rituxan (Rituximab) (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louisiana State University Health Sciences Center Shreveport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Louisiana State University Health Sciences Center Shreveport</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2 Study of VELCADE (bortezomib), Nipent (pentostatin), and Rituxan&#xD;
      (rituximab) (VNR) in Subjects with Relapsed Follicular, Marginal Zone, and Mantle Cell&#xD;
      Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of Subjects: During the Phase 1 part of the study as many as 15 subjects may be&#xD;
      enrolled, based on the dose escalation scheme; the actual number of subjects enrolled will&#xD;
      depend on the dose level at which the maximum tolerated dose (MTD) is established.&#xD;
&#xD;
      During the Phase 2 part of the study, approximately 15 subjects will be enrolled in order to&#xD;
      obtain a total 30 response-evaluable subjects.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
      The primary objectives of this study are:&#xD;
&#xD;
      â€¢ Assess the CR and ORR following treatment with VELCADE (bortezomib), Nipent (pentostatin)&#xD;
      and Rituxan (rituximab) (VNR) in subjects with follicular lymphoma (FL), marginal zone&#xD;
      lymphoma (MZL), and mantle cell lymphoma (MCL) who have relapsed or been refractory after&#xD;
      receiving at least 1 prior therapy.&#xD;
&#xD;
      The secondary objectives of this study are to:&#xD;
&#xD;
        -  Determine the MTD of VELCADE and Nipent in combination with Rituxan (VNR) in subjects&#xD;
           with follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma&#xD;
           (MCL) who have relapsed or been refractory after receiving at least 1 prior therapy&#xD;
&#xD;
        -  Evaluate the safety and tolerability of VNR&#xD;
&#xD;
        -  Determine the time to response&#xD;
&#xD;
        -  Determine duration of response&#xD;
&#xD;
        -  Determine the time to progression (TTP)&#xD;
&#xD;
        -  Determine the progression free survival (PFS) rate&#xD;
&#xD;
        -  Determine the 1-year survival&#xD;
&#xD;
        -  Determine overall survival (OS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator has relocated to MD Anderson&#xD;
  </why_stopped>
  <start_date type="Actual">May 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of progression of disease</measure>
    <time_frame>Study Days 1, 4, 8, 11 of 6 cycles (up to 3 weeks each) and Days 63/126, then Study Months 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 and 48</time_frame>
    <description>Summary data on time to progression of disease of study subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: establish MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: The MTD from Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTD of Velcade, Nipent and Rituxan established in Part 1</intervention_name>
    <description>One of the following dose levels will be chosen and used in Part 2:&#xD;
(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1&#xD;
(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1&#xD;
(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1&#xD;
(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1</description>
    <arm_group_label>Part 1: establish MTD</arm_group_label>
    <arm_group_label>Part 2: The MTD from Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary written informed consent.&#xD;
&#xD;
          2. Male or female subject 18 years of age and older&#xD;
&#xD;
          3. Karnofsky Performance Status (KPS) score of 50%. ECOG Performance Status score greater&#xD;
             than 2.&#xD;
&#xD;
          4. Histologically confirmed follicular Grade 1-3a, marginal zone or mantle cell NHL.&#xD;
&#xD;
          5. Relapsed or progressive disease after at least 1 prior chemotherapy requiring&#xD;
             treatment.&#xD;
&#xD;
          6. Bi-dimensionally measurable disease with at least 1 lesion 2 cm in a single dimension&#xD;
&#xD;
          7. Hematologic, hepatic, and renal function parameters.&#xD;
&#xD;
          8. Recovered fully from any significant toxicity associated with prior surgery, radiation&#xD;
             treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell&#xD;
             transplant, or investigational drugs&#xD;
&#xD;
          9. Expected survival of 3 months&#xD;
&#xD;
         10. Accepted birth control methods during treatment and for 12 months after completion of&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Follicular lymphoma Grade 3b&#xD;
&#xD;
          2. History of allergy to any of the study medications, their analogues, murine proteins,&#xD;
             or excipients in the various formulations&#xD;
&#xD;
          3. Grade 2 peripheral neuropathy or clinical examination within 14 days before enrollment&#xD;
&#xD;
          4. Serum creatinine 2.5 mg/dL within 14 days before enrollment.&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) &lt; 1,000/L, platelet count &lt; 70,000/L within 14 days&#xD;
             before enrollment&#xD;
&#xD;
          6. Aspartate transaminase (AST [SGOT]) and alanine transaminase (ALT/SGPT]) &gt; 2 x the&#xD;
             upper limit of normal (ULN), total bilirubin &gt; 3 ULN&#xD;
&#xD;
          7. Rituxan refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior&#xD;
             Rituxan or prior Rituxan-containing regimen, or a response with a TTP of less than 6&#xD;
             months)&#xD;
&#xD;
          8. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study&#xD;
             Day 1 (6 weeks if nitrosurea or mytomycin-C)&#xD;
&#xD;
          9. Prior lymphoma vaccine therapy within 12 months to Study Day 1&#xD;
&#xD;
         10. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months&#xD;
             prior to Study Day 1&#xD;
&#xD;
         11. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1&#xD;
&#xD;
         12. Known history of hepatitis or hepatic disease.&#xD;
&#xD;
         13. Presence of central nervous system (CNS) lymphoma&#xD;
&#xD;
         14. Known history of HIV infection or AIDS&#xD;
&#xD;
         15. Histologic transformation (Follicular or Marginal zone to diffuse large B cell&#xD;
             lymphoma [DLBCL]&#xD;
&#xD;
         16. Presence of pleural or peritoneal effusion with positive cytology for lymphoma&#xD;
&#xD;
         17. Another primary malignancy requiring active treatment&#xD;
&#xD;
         18. Serious non-malignant disease (e.g., congestive heart failure [CHF], hydronephrosis);&#xD;
             active uncontrolled bacterial, viral, or fungal infections; or other conditions&#xD;
             (including psychiatric), which would compromise protocol objectives n the opinion of&#xD;
             the Investigator and/or Sponsor&#xD;
&#xD;
         19. New York Heart Association Class III or IV (Appendix D) cardiac disease&#xD;
&#xD;
         20. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1&#xD;
&#xD;
         21. Female subject who is pregnant or currently breast-feeding&#xD;
&#xD;
         22. Received other investigational drugs with 14 days before enrollment&#xD;
&#xD;
         23. Hypersensitivity to bortezomib, pentostatin, rituximab, boron or mannitol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Turturro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LSUHSC-S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2011</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center Shreveport</investigator_affiliation>
    <investigator_full_name>Glenn Mills</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Follicular</keyword>
  <keyword>Marginal Zone</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Velcade</keyword>
  <keyword>bortezomib</keyword>
  <keyword>Nipent</keyword>
  <keyword>pentastatin</keyword>
  <keyword>Rituxan</keyword>
  <keyword>rituximab</keyword>
  <keyword>Turturro</keyword>
  <keyword>Shreveport</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

